



Pharmaceutical POOL

Timothy HAYES

Bayer Adds Global Business Development Oversight



Timothy Hayes, currently senior VP and region head for Bayer HealthCare's Consumer Care division in North America, has assumed the additional responsibility of leading the business unit's global business development function.

In addition to his role leading Bayer HealthCare's over-the-counter (OTC) drug business in the United States, Canada, and Puerto Rico, Mr. Hayes now oversees new business development for Consumer Care's global brand portfolio and markets, identifying and analyzing new and emerging opportunities, and developing short- and long-term strategic plans for business growth.

Karen LACKEY

Roche Selects Former GSK VP as Head of Medicinal Chemistry



Karen Lackey has joined Roche as VP and head of medicinal chemistry, responsible for small-molecule drug discovery in oncology, virology, and inflammation.

Ms. Lackey is also overseeing the Nutley, N.J.-based discovery chemistry management team as a member of the global chemistry leadership team.

Most recently, Ms. Lackey was VP, discovery medicine chemistry, at GlaxoSmithKline.

Biotechnology POOL

Timothy KING

Dr. Herve

MOMMEJA-MARIN

Chimerix Adds Two VPs to Clinical Management Team



Chimerix, a biotechnology company developing orally available antiviral therapeutics, has appointed Timothy King VP of clinical operations in charge of overseeing clinical operations and site management.

Mr. King was most recently a group director at Quintiles.

Herve Mommeja-Marin, M.D., has been named VP of clinical research, with responsibility for overseeing clinical strategy and study design.

Dr. Mommeja-Marin joins Chimerix from i3 Research, where he served as senior medical director, infectious diseases.

Dr. George

TIDMARSH

Spectrum Pharmaceuticals Names R&D Head



Spectrum Pharmaceuticals, a biotechnology company primarily focused on hematology and oncology, has named George Tidmarsh, M.D., Ph.D., senior VP, chief scientific officer and head of research and development operations.

Dr. Tidmarsh founded Horizon Pharma and Threshold Pharmaceuticals, taking Threshold public in 2005 and guiding Horizon to successful completion of its Phase III clinical program.

He also has held various positions at Coulter Pharmaceuticals, including chief medical officer.

Dr. Tidmarsh received an M.D. and a Ph.D. from Stanford University School of Medicine, where he also completed fellowships in pediatric oncology and neonatal intensive care.

Biopharmaceutical POOL

Dr. Christine BRENNAN

Former Novartis Executive Joins Vitae Pharmaceuticals

Vitae Pharmaceuticals has appointed Christine Brennan, Ph.D., chief business officer.

Dr. Brennan most recently served as executive director and head of strategy and operations for strategic alliances at the Novartis Institutes for BioMedical Research. She received a Ph.D. in neuroscience from Dartmouth Medical School.

Vitae Pharmaceuticals is a development-stage biopharmaceutical company building a portfolio of novel small-molecule compounds.



Specialty POOL

Steve

ANDRZEJEWSKI

Nycomed US Announces New CEO



Nycomed US has named Steve Andrzejewski CEO, with responsibility for the dermatology specialty company's manufacturing operations in Melville and Hicksville, N.Y.

He also oversees distribution and commercial operations for its three marketing and sales divisions: Fougera, PharmaDerm, and Savage Laboratories.

Mr. Andrzejewski was previously chief commercial officer for King Pharmaceuticals. He received an MBA in finance/international business from New York University.

Association **POOL**

Gabriella (Gabby) **CRUZE**

Society for Translational Oncology Names Executive Director



The Society for Translational Oncology (STO) has named Gabriella (Gabby) Cruze as its inaugural executive director. Ms. Cruze joins STO from Scienta Healthcare Education. Ms.

Cruze's responsibilities include focusing on the growth of STO's physician education programs and leading efforts to establish productive alliances with other providers of healthcare education. STO is a nonprofit association whose mission is to speed the discovery and translation of important new treatments in the field of cancer medicine.



positive outcomes, has made a number of additions and promotions to its growing organization.

Julie Bernardini has been promoted to VP, creative director, from creative director.



Martin Bunyi has joined HealthEd as senior digital art director. Mr. Bunyi's previous experience includes stints as an art director at Idea Integration, Spiketv.com, and Digitas.



Laura Catalusci has been appointed health education specialist. Previously, Ms. Catalusci was a consultant for an interactive agency.




Sarah Flynn has joined the agency as senior account executive. Ms. Flynn was most recently director for client services with MediMedia Educational Group.



James Gibson has been named senior copywriter. Mr. Gibson was previously a senior copywriter with MRM Gillespie and QLM Marketing.



Joseph Giuliani has been appointed business manager, operations. Mr. Giuliani was most recently in account services with Noesis.



Erik Gudowski has been named VP, digital creative director, for HealthEd Digital. Before joining HealthEd, Mr.

Gudowski was owner of visual communications company TouchPoint Orange.

Katherine Margolis has assumed the role of manager, health education. Before joining HealthEd, Ms. Margolis was a research scientist for the Centers for Disease Control and Prevention at the National Institute for Occupational Safety and Health.

Julia Olff has been promoted to VP, health education, from her previous position of director, health education.

Luis Perez has been named a senior developer for HealthEd On Demand. Most recently, Mr. Perez was a project lead developer for Barnes & Noble.

Raffaele Piemonte has been appointed chief technology officer. Most recently, Mr. Piemonte served as director of application integration services with KPMG.




Debra Podolsky has been promoted to account supervisor, account services, from her previous position of senior account executive.



Kevin Purcell has been elevated to copy director, creative services, from copy supervisor.



Tanvi Shah joins HealthEd as senior account executive. Most recently, Ms. Shah was a senior business analyst/product manager, e-business services for Johnson & Johnson Health Care Systems.



Jennifer Sigaud has been named VP, account director, helping to manage two key

brands for Encore, a HealthEd company. Most recently, Ms. Sigaud was VP for client services for MediMedia Educational Group.

Bruce **JENKINS**

Boomerang Adds Interactive Services VP

Boomerang Pharmaceutical Communications, a healthcare interactive agency, has appointed Bruce Jenkins VP of interactive services, with a leadership role in interactive business development and the management of e-marketing and creative strategies. Mr. Jenkins has two decades of healthcare communications experience.



Hana **SMETKOVA**

Ignite Health Appoints Creative Director

Ignite Health, an inVentiv Health company and marketing agency specializing in patient-centered medical advertising, has hired Hana Smetkova as VP, creative director, with responsibility for creative oversight and strategic development for the agency's New York office. Ms. Smetkova joins Ignite from CCG Metamedia.



Consulting **POOL**

Adel **AL-SALEH**

IMS Health Adds Global Account VP

IMS Health, a global provider of market

Agency **POOL**

Julie **BERNARDINI**

Martin **BUNYI**

Laura **CATALUSCI**

Sarah **FLYNN**

James **GIBSON**

Joseph **GIULINI**

Erik **GUDOWSKI**

Katherine **MARGOLIS**

Julia **OLFF**

Luis **PEREZ**

Raffaele **PIEMONTE**

Debra **PODOLSKY**

Kevin **PURCELL**

Tanvi **SHAH**

Jennifer **SIGAUD**

HealthEd Makes Staff Changes

HealthEd, a specialized healthcare marketing agency focused on turning education into



intelligence to the pharmaceutical and healthcare industries, has promoted Adel Al-Saleh to the newly created role of senior VP, sales and global account management. Previously, Mr. Al-Saleh was president, Europe, Middle East, and Africa, for IMS.

Mr. Al-Saleh is responsible for advancing the company's go-to-market initiatives, working closely with the sales, consulting, services and business line organizations. He also oversees the company's global key account management efforts, driving sales activities with multinational clients. He has an MBA from Florida Atlantic University.

CRO POOL

Riaz **BANDALI**

Dr. Wolfgang **RENZ**

PharmaNet Development Group Expands Clinical Development Team



Global drug development services provider PharmaNet Development Group has named Riaz Bandali president, early stage development. Mr. Bandali is responsible for the leadership of PharmaNet's early-stage clinical development business, which includes Phase I clinics and bioanalytical laboratories. He joins PharmaNet from AB Sciex and Molecular Devices.



Mr. Bandali holds an MBA from McGill University in Montreal and completed Harvard Business School's Advanced Management Program.

In other moves, Wolfgang Renz, M.D., has been appointed senior VP, clinical operations. Dr. Renz is based in Zurich and has responsibility for PharmaNet's clinical operations in Europe and the regional monitoring group in North America. Dr. Renz's previous experience includes stints as general manager of JSS Medical Research, president of Samaritan Therapeutics, and CEO of Venn Life Sciences Holdings. He has a medical degree from the University of Freiburg in Germany.

Dr. Michael **GALLAGHER**

Kendle Appoints Global Medical Affairs VP

Full-service clinical research organization



Kendle International has named Michael Gallagher, M.D., VP and global head, medical affairs. Dr. Gallagher was most recently the global gastrointestinal therapeutic area group leader for Icon Clinical Research. He received a medical degree from the Universidad Federico Henriquez y Carvajal in the Dominican Republic.

Dr. John **KAMERUD**

Covance Strengthens Chemistry Services



John Kamerud, Ph.D., has joined Covance as associate director of immunochemistry services, with responsibility for leading the drug development services company's North American principal investigator teams providing large molecule bioanalytical services.

Dr. Kamerud was most recently with Lilly, where he served as research advisor and principal investigator. He received a doctorate in biochemistry from the University of Minnesota.

Dr. Henrietta **UKWU**

PPD Names Regulatory Affairs VP



Global contract research organization PPD has appointed Henrietta Ukwu, M.D., as senior VP of global regulatory affairs, with global responsibility for regulatory services across all PPD's businesses. Dr. Ukwu is also responsible for providing clinical vaccine expertise.

Dr. Ukwu most recently served as VP of global regulatory affairs at Wyeth Pharmaceuticals. She earned medical and surgical degrees from the Medical School at the University of Jos in Nigeria.

Service POOL

Marcie **GOODALE**

Tita **JETER**

Tim **SCHUCKMAN**

Bill **VAN NOSTRAND**

Copernicus Group Adds Staff

Independent institutional review board



Copernicus Group IRB (CGIRB) has made a number of appointments to its business development and regulatory compliance teams.

Marcie Goodale has joined CGIRB as regional director of business development.

Ms. Goodale was previously director of business development at ePharma Solutions.

Tita Jeter has been hired as manager of quality assurance and regulatory compliance.

Ms. Jeter was most recently with Duke Clinical Research Institute.

Tim Schuckman has been appointed regional director of business development.

Mr. Schuckman joins CGIRB from GLS (Global Language Solutions), where he was global director of business development.

Bill Van Nostrand has been named VP and chief business development officer, overseeing all business development and marketing activities.

Mr. Van Nostrand joins CGIRB from Medical Marketing Solutions, a strategic consulting business he ran for the past five years.

Dr. Mohamed **HACHICHA**

NexMed Strengthens U.S.-Based Executive Team



NexMed has appointed Mohamed Hachicha, Ph.D., VP, research and development, for its U.S. business.

Dr. Hachicha brings to NexMed 15 years of experience in the pharmaceutical and biotechnology field and was most recently senior principal scientist in the pharmacology and drug discovery department at Forest Laboratories. While at Forest, he was responsible for managing and coordinating two of the company's discovery research programs.

He received an M.Sc. and a Ph.D., both in immunology, from Université Laval in Québec City, Canada.

NexMed is a specialty CRO offering in vitro and in vivo pharmacology services and research models. ♦

Send your personnel announcements to feedback@pharmavoices.com.

Specialty Pharma Commercial Excellence Summit

15-16th November, Boston

**Beyond Blockbusters: Re-energize your
Sales Strategy with Specialty Success**

Hear from 10 VPs including:

- › **Barry Duke**
Vice President of Sales
Genzyme
- › **Tyrone Edwards**
Senior Vice President
Merck (ret.)
- › **Joesph Caminiti**
Vice President of Sales
Cephalon
- › **Jerry Conway**
VP Managed Markets
Genzyme
- › **Gaston Bernstein**
*Vice President and
General Manager*
**CoramRx Specialty
Pharmacy**
- › **Heidi Wagner**
*Vice President Global
Government Affairs*
Alexion Pharmaceutical
- › **Charlotte Sibley**
Senior Vice President
Shire
- › **Leeland Wilson**
CEO
Vivus

**The world's first
Specialty
conference
focused towards
both big and
small pharma**

Save \$300
mention PharmaVoice
when you register

www.eyeforpharma.com/specialtypharma



Developed by:

pharma

TALENT pool

Biotechnology **POOL**

Dr. Antonin (Tony)

DE FOUGEROLLES

Tolerx Appoints Scientific Chief

Tolerx, a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer, has named Antonin (Tony) de Fougerolles, Ph.D., chief scientific officer. Dr. de Fougerolles is responsible for directing the company's R&D activities and strengthening Tolerx's leadership in T-cell immunology.

Dr. de Fougerolles was previously VP, research, immunology, metabolic, and viral disease at Alnylam Pharmaceuticals. He earned a Ph.D. in immunology from Harvard University and was a research fellow at the Laboratory of Molecular Biology in Cambridge, England.

Dr. Terence (Terry) **RYAN**

Former Wyeth Executive Joins iBio as Business Development VP

iBio, a biotech company commercializing its iBioLaunch technology platform for the production of biologics, has appointed Terence (Terry) Ryan, Ph.D., senior VP, business development, responsible for all aspects of new business development, including cultivating relationships with major pharmaceutical companies and procuring grants and awards from government agencies.

Mr. Ryan recently served as assistant VP, biological technologies, discovery research, with Wyeth (now Pfizer) Research. He received an M.S. and a Ph.D. in microbiology, both from Rutgers University.

Biopharmaceutical **POOL**Dr. Charles **JOHNSON**

Inspire Pharmaceuticals Names R&D Head

Inspire Pharmaceuticals, a biopharmaceutical company focused on researching, developing, and commercializing products for ophthalmic and pulmonary diseases, has named Charles Johnson, M.D., executive VP of research and development and chief medical officer. Dr. Johnson was previously chief medical officer at Apt Pharmaceuticals.

Dr. Johnson received a medical degree from

the University of Cape Town in South Africa, gained board certification in pediatrics at the Red Cross War Memorial Children's Hospital in South Africa, and completed a pediatric pulmonology fellowship at Washington University in St. Louis.

Dr. Terence **KELLY**

CoMentis Taps Boehringer Ingelheim Veteran as Discovery VP

CoMentis has appointed Terence Kelly, Ph.D., senior VP for discovery and preclinical development, with responsibility for the Oklahoma City research group. CoMentis is a privately held biopharma company engaged in the discovery and development of small-molecule drugs to treat Alzheimer's disease.

Dr. Kelly joins CoMentis after almost 20 years at Boehringer Ingelheim, most recently as VP of chemistry. Dr. Kelly received a Ph.D. in chemistry from the University of Texas at Austin and an MBA from New York University, Stern School of Business.

Dr. Martin **MEGLASSON**

Ikaria Appoints Early-Stage Science Chief

Ikaria, a biotherapeutics company focused on developing and commercializing therapeutics addressing the unmet needs of critically ill patients, has named Martin Meglasson, Ph.D., chief science officer responsible for activities related to early-stage drug development. Dr. Meglasson joins Ikaria from Ligand Pharmaceuticals, where he was most recently VP of discovery research.

Specialty **POOL**John **BAILYE**Bill **MCKEE**

New Leadership at EKR Therapeutics

EKR Therapeutics, a privately held specialty pharmaceutical company focused on providing critical care products to the hospital marketplace, has appointed John Bailye CEO. Mr. Bailye is the founder and former chairman of Dendrite International and joined EKR as executive chairman in September 2009.

In other moves, Bill McKee has been named chief operating officer and chief financial officer. Mr. McKee comes to EKR after a

15-year career with Barr Pharmaceuticals, most recently as executive VP and CFO.

Device/Diagnostic **POOL**Chip **CLARK**

Genocea Hires Business Chief

Genocea Biosciences, a discovery and development company pioneering a new class of T-cell-based vaccines, has named Chip Clark chief business officer. Mr. Clark previously held the same position at Vanda Pharmaceuticals, a biopharmaceutical company he co-founded in 2004. He received an MBA from The Wharton School at the University of Pennsylvania.

Dr. Mark **MINTUN**

Avid Radiopharmaceuticals Hires Medical Chief

Avid Radiopharmaceuticals has appointed Mark Mintun, M.D., chief medical officer. Avid develops molecular imaging agents designed to detect, diagnose, and monitor major chronic human diseases, such as Alzheimer's disease, Parkinson's disease, and diabetes. Dr. Mintun brings extensive research, clinical, and management experience to Avid, most recently serving as vice chair for research and director of the Center for Clinical Imaging Research at the Mallinckrodt Institute of Radiology at Washington University School of Medicine in St. Louis. He received a medical degree from Washington University.

Discovery **POOL**Dr. Richard **HEYMAN**

Aragon Pharmaceuticals Co-Founder Assumes CEO Role

Aragon Pharmaceuticals, a privately held, small-molecule drug discovery company identifying medicines for hormonally driven cancers, has named Richard Heyman, Ph.D., CEO. Before co-founding Aragon in 2009, Dr. Heyman served as chief scientific officer at Kalypsys. He received a Ph.D. in pharmacology from the University of Minnesota and was a National Institutes of Health postdoctoral fellow and staff scientist at the Salk Institute for Biological Studies.

Agency POOL

Matt GARDNER

MS&LGroup Strengthens Healthcare Practice

Global communications firm MS&LGroup, part of Publicis Groupe, has expanded its healthcare practice in North America with the addition of biotech industry veteran Matt Gardner as senior VP to lead the agency's western U.S. region healthcare team based in San Francisco. Mr. Gardner is also focused on building MS&LGroup's life-sciences offering.

Mr. Gardner was most recently president and CEO of Baybio, the trade association for the life-sciences industry in northern California.

Kate GOMULKA

Chris TAORMINA

Mike WELLBORN

Roska Healthcare Bolsters Digital Expertise

Roska Healthcare Advertising has made a number of additions to strengthen its digital service offerings.

Kate Gomulka has joined Roska as associate media planner, with primary responsibility for execution and management of social media and search engine marketing strategies, website analytics, and digital landscape reporting for pharmaceutical and healthcare clients. She was most recently with Cowden Associates.

Chris Taormina has been named executive director, leading the Roska digital team in delivery of innovative solutions and providing insight into leveraging emerging technology and digital media to achieve the strategic vision of the brand and organization. In addition, Mr. Taormina is responsible for Roska's development, project management, and quality assurance teams and serves as a strategic digital liaison to client stakeholders for all customer engagements and the Roska executive committee.

Mr. Taormina's 15-plus years of digital program manager and strategist experience includes stints at Rosetta, IMC2, and ProjecTechs.

Mike Wellborn has joined Roska as a Web developer. Mr. Wellborn previously worked for The Bancorp Bank, where he developed customized financial Web platforms for the bank's online affiliates.

CRO POOL

Naren MALLAKUNTA

Laxai Pharma Formalizes CEO Appointment

International contract research organization Laxai Pharma has appointed Naren Mallakunta to its full-time management team as CEO. Mr. Mallakunta was previously interim CEO of Laxai.

Service POOL

Tracy HENDERSHOTT

Dr. Cholpady KAMATH

Dr. Hua-Kang WU

ACM Global Adds to U.S. Staff

Central laboratory services provider ACM Global Central Lab has promoted Tracy Hendershott to executive director, global operations.

Mr. Hendershott is responsible for overseeing the strategy, standardization, and integration of ACM Global's facilities and partner labs as the company continues to expand its global footprint.

Cholpady Kamath, M.D., has been named director of anatomic pathology. Dr. Kamath is board-certified in anatomic and clinical pathology.

ACM Global has also invested in scientific expertise with the appointment of Hua-Kang Wu, Ph.D., as director of molecular and cellular diagnostics.

Technology POOL

Chip ALEXANDER

Gonzalo CASTRO

Dr. Jin HUANG

iMany Expands Executive Team

iMany, a provider of contract performance solutions, has added three executives to its development team.

Chip Alexander has been named chief architect of user interface and experience, responsible for user-centered design best practices, methodologies, and standards around iMany's ContractSphere platform. Before joining iMany, Mr. Alexander was a user interface architect at both Oracle and Sun Microsystems.

Gonzalo Castro has joined iMany as VP of product management. Mr. Castro directs product management and ensures alignment of the ContractSphere platform with customer needs and industry demands.

He was most recently VP of product marketing for DecisionView. Mr. Castro has an MBA from the Wharton School of the University of Pennsylvania.

In other moves, iMany has promoted Jin Huang, Ph.D., to VP of development from his previous role as senior director of engineering and program management. Dr. Huang is responsible for architecture, engineering, and quality assurance of the entire iMany family of products.

He received both an M.S. in CAD/CAM and a Ph.D. in computer integrated engineering systems from Xi'an Jiao Tong University in Xi'an, China. He also holds an M.S. in computer science from the University of North Carolina at Charlotte. ♦



PharmaVOICE
MarketPlace.com

**More than 5,500
Solutions Providers**

The most comprehensive online directory of products and services for the life-sciences industry — featuring a wide range of products, services, and solutions for your clinical, commercial, business, and technology needs.

Browse by Category • Search by Company

www.pharmavoicemarketplace.com